HƯỚNG DẪN ngành
FDA Regulation of AI Medical Devices
In the United States, AI software that diagnoses, treats, or informs care for a patient is usually regulated by the FDA as a medical device.
Trên trang nàyđọc 4 phút
Tổng quan
It reaches the market through one of three main routes: 510(k) clearance, De Novo classification, or premarket approval (PMA). This matters because it decides what evidence a developer must produce, how an AI model can be updated after launch, and how much doctors and patients can trust the tool.
Lặn sâu
The FDA regulates software by its intended use, not by the technology inside it. If software is meant to diagnose, treat, prevent, or mitigate disease, it is generally a device; standalone software of this kind is called Software as a Medical Device (SaMD). Devices fall into Class I, II, or III by risk, and the class largely sets the pathway. Most AI-enabled devices reach the market through 510(k) clearance, in which the manufacturer shows substantial equivalence to a legally marketed "predicate" device. When a novel device is low to moderate risk and has no predicate, the De Novo pathway creates a new classification that later devices can use as a predicate. Premarket approval (PMA), the strictest route, is reserved for high-risk Class III devices and usually requires clinical evidence. The FDA's public list of authorized AI-enabled devices now runs to more than a thousand products, most of them in radiology. Not all health software is a device. The 21st Century Cures Act (2016) excludes certain clinical decision support tools. To qualify, the tool must show clinicians the basis for its recommendations so they can review them independently, and it must not analyze medical images or signals. Traditionally, a significant change to a cleared device needs a new submission. The Food and Drug Omnibus Reform Act of 2022 gave the FDA authority to approve predetermined change control plans (PCCPs), and the FDA finalized guidance for AI-enabled devices in December 2024. A PCCP lets a manufacturer make specified, pre-validated changes without filing again. A common misconception is that cleared AI devices learn on their own in the field. Most authorized models are "locked": they change only through controlled, versioned updates. In the EU, the Medical Device Regulation (MDR) classifies software under Rule 11, which puts most diagnostic software in Class IIa or higher and so requires notified body review. The EU AI Act adds high-risk AI obligations for these devices, phasing in later than most of the Act.
Tác động chiến lược
Bối cảnh và quy tắc
Bối cảnh của ngành quyết định liệu các ý tưởng AI có tồn tại được khi tiếp xúc với thực tế hay không.
Kiểm soát chất lượng
Các ràng buộc về miền ảnh hưởng đến tỷ lệ lỗi có thể chấp nhận được và các mô hình giám sát.
Xây dựng lựa chọn
Triển khai thành công sẽ điều chỉnh năng lực kỹ thuật phù hợp với quy trình làm việc tuyến đầu.
The Future of FDA Regulation of AI Medical Devices
The main open question is generative AI. Large language models produce open-ended output that is hard to validate the way a fixed classifier is validated. The FDA's Digital Health Advisory Committee held its first meeting on generative AI-enabled devices in November 2024. Expect more attention to monitoring real-world performance after deployment, to transparency about training data, and to greater use of PCCPs as manufacturers learn what the FDA will accept. In Europe, companies face overlapping MDR and AI Act requirements. Guidance on how the two fit together, and whether notified bodies have enough capacity, will shape how quickly AI devices reach patients there.
Triển khai trong thế giới thực
A radiology startup builds software that flags suspected brain bleeds on CT scans and moves them up the reading queue. It gets 510(k) clearance by showing substantial equivalence to a triage tool that is already cleared.
IDx-DR (now LumineticsCore) detects diabetic retinopathy in retinal photos without a specialist reading the image. There was no predicate device, so the FDA authorized it through the De Novo pathway in 2018.
A maker of ECG analysis software submits a predetermined change control plan (PCCP) with its application. The plan describes how the company will retrain the model on new data and what tests each update must pass, so those updates do not each need a new submission.
A company selling the same imaging AI in Europe must get a CE mark under the EU Medical Device Regulation through a notified body. It must also prepare for the EU AI Act, which treats such products as high-risk AI systems.
Rủi ro & lan can
Các yêu cầu pháp lý có thể vô hiệu hóa các nguyên mẫu mạnh mẽ.
Dữ liệu lịch sử có thể mã hóa thành kiến gây tổn hại cho các cộng đồng cụ thể.
Các hệ thống cũ có thể tạo ra các nút thắt cổ chai trong tích hợp và chi phí tiềm ẩn.
Lộ trình thực hiện
Thu hút các chuyên gia trong lĩnh vực từ việc xác định vấn đề đến đánh giá.
Thiết kế các đường dẫn kiểm tra và tài liệu trước khi ra mắt.
Xác nhận sớm các nghĩa vụ tuân thủ và an toàn.
Triển khai theo từng giai đoạn với tiêu chí dừng và khôi phục rõ ràng.
Tiếp tục khám phá
Free newsletter
Get the daily AI briefing
Three verified AI stories every weekday morning, written in plain English. Free forever, no ads.
One email each weekday. Unsubscribe in one click. We never sell or share your address.
Test yourself
Take the FDA Regulation of AI Medical Devices quiz
Instant feedback on every answer, and a shareable certificate with a verifiable ID once you pass a course.
Support free AI education. AI Understanding is a 501(c)(3) nonprofit — no ads, no paywall, ever. Make a donation
Câu hỏi thường gặp
What is FDA Regulation of AI Medical Devices?
In the United States, AI software that diagnoses, treats, or informs care for a patient is usually regulated by the FDA as a medical device. It reaches the market through one of three main routes: 510(k) clearance, De Novo classification, or premarket approval (PMA). This matters because it decides what evidence a developer must produce, how an AI model can be updated after launch, and how much doctors and patients can trust the tool.
What must a manufacturer show to obtain 510(k) clearance?
A 510(k) rests on substantial equivalence to an existing predicate. Most AI-enabled devices reach the market this way.
The FDA authorized IDx-DR, an autonomous AI for diabetic retinopathy, in 2018. Which pathway did it use, and why?
De Novo is for novel low-to-moderate-risk devices with no predicate. Once a device is authorized this way, later devices can use it as a predicate.
What does a predetermined change control plan (PCCP) allow?
A PCCP authorizes planned changes, such as retraining, in advance, along with the protocol used to validate them. Changes outside the plan still need a new submission.
Which three parts make up a PCCP?
A PCCP describes the planned changes, sets out how they will be developed and validated, and assesses their benefits and risks.
Which statement about most FDA-authorized AI devices is accurate?
Most authorized AI models are locked. Updates come as controlled versions, and radiology, not dermatology, accounts for most authorized AI devices.
Tiếp tục học hỏi
Hướng dẫn liên quan
Đã chọn thêm hướng dẫn cho chủ đề này